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(57) ABSTRACT 
Compounds of Formula (I), and methods of making and using 
thereof, are described herein; wherein AR is an aryl group, 
ZBG is a Zinc Binding Group, and other substituents are as 
defined herein. The compounds can be administered as a 
pharmaceutically acceptable salt, prodrug, or solvate. The 
compounds may be useful to treat and/or prevent hyperpro-
liferative disorders which may include hormone sensitive and 
hormone refractory prostate cancers. The compounds can be 
formulated with a pharmaceutically acceptable carrier and, 
optionally one or more pharmaceutically acceptable excipi-
ents, for enteral or parenteral administration. 
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HISTONE DEACETYLASE (HDAC) 
INHIBITORS TARGETING PROSTATE 
TUMORS AND METHODS OF MAKING AND 
USING THEREOF 
RELATED APPLICATIONS 
This application is a 35 U.S.C. §371 national phase entry of 
PCT Application PCT/US2011/053623, filed Sep. 28, 2011, 
and published in English on Apr. 19, 2012, as International 
Publication No. WO 2012/050868, and which claims the 
benefit of U.S. Provisional Patent Application Ser. No. 
61/387,183, filed Sep. 28, 2010, the disclosure of each of 
which is incorporated by reference herein in its entirety. 
STATEMENT OF GOVERNMENT SUPPORT 
This invention was made with Government support under 
Grant No. 1R01CA131217-01A2. The US Government has 
certain rights to this invention. 
FIELD OF THE INVENTION 
The present invention generally relates to histone deacety-
lase (HDAC) inhibitors that target prostate tumor. More par-
ticularly, the invention describes a series of arylhydantoin 
derived HDAC inhibitors that target androgen positive pros-
tate tumors through their interaction with androgen receptor 
to facilitate selective uptake into and/or retention in the tumor 
cell. The invention describes the methods for making and 
using thereof. 
BACKGROUND OF THE INVENTION 
Prostate cancer remains the most common form of cancer 
among all males in the US, with black men at highest risk 
(Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J., 
Cancer Statistics, 2009. CA Cancer J Clin 2009, caac.20006). 
It is also the second leading cause of cancer related deaths in 
the US among men, largely due to the progressively treatment 
resistant nature of the disease. Treatment options for early 
stage prostate cancer commonly involve various combina-
tions of watchful waiting, radical prostatectomy, radiation 
therapy, and very importantly, androgen-deprivation therapy 
(ADT) (Georgi, P.; Ronald, L. H.; Joel, B. N., The Treatment 
of Prostate Cancer.&nbsp. Cancer Practice 2001, 9 (6), 295-
306). Prostate cancer is dependent upon androgen hormone 
steroids such as dihydrotestosterone (DHT) for sustaining 
and promoting growth. They do this by binding to the Andro-
gen Receptor (AR) and localizing to the nucleus where it 
forms a complex that up regulates the transcription of critical 
genes. ADT is accomplished by either (i) administering 
antagonist to the AR that blocks androgen ligands (such as 
DHT), or by (ii) castration, in order to reduce the amount of 
testosterone available. Often both methods of ADT are used. 
However, the disease frequently advances to the much more 
lethal castration-resistant prostate cancer (CRPC), becoming 
resistant to these therapies by overexpressing ARs (Chen, C. 
D.; Welsbie, D. S.; Tran, C.; Baek, S. H.; Chen, R.; Vessella, 
R.; Rosenfeld, M. G.; Sawyers, C. L., Molecular determi-
nants of resistance to antiandrogen therapy. Nature Medicine 
2004, 10 (1), 33-39; Papatsoris, A.G.; Karamouzis, M. V.; 
Papavassiliou, A. G., Novel biological agents for the treat-
ment ofhormone-refractory prostate cancer (HRPC). Current 
Medicinal Chemistry 2005, 12 (3), 277-296). The expression 
levels of AR is about six-fold higher in castration resistant as 
compared to hormone-sensitive prostate cancer (inj a, M. J.; 
2 
Savinainen, K. J.; Saramaki, 0. R.; Tammela, T. L. J.; Ves-
sella, R. L.; Visakorpi, T., Amplification and overexpression 
of androgen receptor gene in hormone-refractory prostate 
cancer. Cancer Res. 2001, 61 (9), 3550-3555). The effective 
5 treatment options for patients at this point have been 
exhausted. Options currently available for CRPC are support-
ive care, salvage endocrine manipulations, radiotherapy, 
radioactive isotopes, bisphosphonates and chemotherapy 
(Lara, P. N.; Meyers, F. J., Treatment options in androgen-
10 independent prostate cancer. Cancer Investigation 1999, 17 
(2), 137-144). These options are not curative. 
The understanding that AR overexpression is one of the 
major causes of hormone refractory prostate cancer, and the 
dependency of the growth of the hormone refractory prostate 
15 on the binding of AR ligands, suggest that AR is a viable 
target for this form of malignancy. The preference of anti-
androgen as agents for prostate cancer therapy is predicated 
on the selectivity and fewer side effects of these agents. The 
discovery and the use thereof of these anti-androgens have 
20 been well documented in several patents such as U.S. Pat. No. 
7,709,517, U.S. Pat. No. 4,097,578, U.S. Pat. No. 5,411,981, 
U.S. Pat. No. 5,705,654, PCT International Applications WO 
97/00071 and WO 00/17163, U.S. Published Patent Applica-
tion No. 200410009969, U.S. Published Patent Application 
25 No. 2007/0004753, U.S. Published Patent Application No. 
2008/0139634 and U.S. Published Patent Application No. 
2010/0172975. However, the anti-androgens in common 
clinical use, such as bicalutamide (brand name: Casodex), 
have curative effects only on hormone sensitive prostate can-
30 cer and not on hormone refractory prostate cancer. The lack of 
the activity of most anti-androgens against refractory prostate 
cancer is partly due to their weak antagonist activities and 
strong agonist activities when AR is overexpressed as in 
refractory prostate cancer. The availability of AR inhibitors 
35 with more potent antagonistic activities and minimal agonis-
tic activities has been described a viable approach to delay the 
progression and/or treat hormone refractory prostate cancer 
(U.S. Pat. No. 7,709,517, U.S. Published Patent Application 
No. 2007/0004753, U.S. Published Patent Application No. 
40 2008/0139634 and U. S. Published Patent Application No. 
2010/0172975). Alternatively, the current anti-androgens, 
including but not limiting to the more potent diary lhydantions 
described in U.S. Pat. No. 7,709,517, U.S. Published Patent 
Application No. 2007 /0004753, U.S. Published PatentAppli-
45 cation No. 2008/0139634 and U.S. Published Patent Appli-
cation No. 2010/0172975, could be designed to incorporate a 
new cancer inhibiting moiety. Our molecular docking analy-
sis revealed that prototypical simple HDAC inhibiting phar-
macophores could ideally function as the new cancer inhib-
50 iting moiety (unpublished results). 
The histone protein complex associates with DNA to form 
the higher order structure called chromatin. The histones are 
bound either loosely to form "beads on a string" that are 
accessible to transcriptional activity, or a tighter chromatin 
55 complex that reduces access to the genetic information. The 
genomic flux is regulated by the tightness of binding through 
modifications such as methylation, acetylation, or phospho-
rylation of the histones (Minucci, S.; Pelicci, P. G., Histone 
deacetylase inhibitors and the promise of epigenetic (and 
60 more) treatments for cancer. Nat. Rev. Cancer 2006, 6 (1), 
38-51). Two families of proteins that are involved in control-
ling the extent of acetylation are histone acetyl transferases 
(HATs), which place an acetyl group onto the lysine of a 
histone protein, and histone deacetylases (HDACs), which 
65 remove it. There are 11 known isoforms ofHDAC enzymes in 
Class I and II, which employ catalytic Zn2+ embedded in the 
active site. In many cancers, including prostate cancer, it has 
US 9, 139,565 B2 
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been observed that there is aberrant transcriptional silencing 
that is the result of HDAC enzymes being in unusually high 
abundance. The up regulation of HDAC activity has been 
connected with the down regulation of key onco-suppressor 
proteins (Martinez-Iglesias, O.; Ruiz-Llorente, L.; Sa~chez- 5 
Martinez, R.; Garcia, L.; Zambrano, A.; Aranda, A., H1stone 
deacetylase inhibitors: mechanism of action and therapeutic 
use in cancer. Clin. Transl. Oneal. 2008, 10 (7), 395-398). 
HDAC inhibition has been validated as a clinically viable 
cancer therapy in recent years. Suberoylanilide hydroxamic 10 
acid (SAHA,) received FDA approval for treatment of cuta-
neous T-cell lymphoma in 2006, along with FK228 which 
gained approval in 2009. Many other HDACi are being enthu-
siastically investigated, with several clinical trials running 
currently (Richan, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; 15 
Breslow, R.; Rifkind, R. A.; Marks, P.A., A class of hybrid 
polar inducers of transformed cell differentiation inhibits his-
tone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (6), 
3003-3007; Tan, J. H.; Cang, S. D.; Ma, Y. H.; Petrillo, R. L.; 
Liu, D. L., Novel histone deacetylase inhibitors in clinical 20 
trials as anti-cancer agents. J. Hematol. Oneal. 2010, 3). One 
of the major drawbacks of present HDAC inhibitors is their 
lack of isoform, tissue, and cell type selectivity, resulting in 
toxicity and low potency. An approach that selectively target 
HDAC inhibitors to the diseased cells could ameliorate many 25 
of these drawbacks. 
All HDAC inhibitors so far reported fit a three-motif phar-
macophoric model namely, a zinc-binding group CZ.BG), a 
hydrophobic linker and a recognition cap-group (Miller, T. 
A.; Witter, D. J.; Belvedere, S.,J. Med. Chem., 46, 5097-5116 30 (2003)). We have observed a convergence of structure activity 
relationship (SAR) between the aryl recognition cap-group of 
HDAC inhibitors and diarylhydantoin anti-androgens that 
enabled the design of arylhydantoin derived HDAC inhibitors 
(unpublished results). These arylhydantoin derived HDA~ 35 
inhibitors, through the interactions between AR and the~r 
anti-androgen moiety, are expected to target androgen posi-
tive prostate tumors and become selectively uptaken into 
and/or retained in the tumor cell. This approach should pro-
vide a highly desirable treatment options that become 40 
increasingly more selective and potent as the disease 
progresses from the hormone sensitive to the hormone refrac-
tory stage. 
It is therefore an object of the invention to provide arylhy-
dantoin derived HDAC inhibitors with improved selectivity 45 
for prostate malignacies and methods of making and using 
thereof. 
SUMMARY OF THE INVENTION 
50 
Compounds of Formula I, and methods of making and 
using thereof, are described herein. 
(I) 55 
4 
A is a linking group connected to AR, 
Bis an alkyl, alkylaryl or alkylheteroaryl spacer group, 
ZBG is a Zinc Binding Group, 
R and R2 are independently selected from groups consist-
ing ~fhydrogen, and/or together from groups comprising 1-8 
carbon atoms, selected from wherein these groups compris-
ing 1-8 carbon atoms are selected from groups consisting of 
alkyl, substituted alkyl including haloalkyl, and, together 
with the carbon to which they are linked, a cycloalkyl or 
substituted cycloalkyl group, 
W is selected from the group consisting of 0 and S, 
X is selected from the group consisting of cyano and nitro, 
Y is selected from the group consisting oftrifluoromethyl 
andiodo. 
The compounds can be administered as a pharmaceutically 
acceptable salt, prodrug, or solvate. The compounds may be 
useful to treat and/or prevent hyperproliferative disorders 
which may include hormone sensitive and hormone refrac-
tory prostate cancers. The compounds described herein can 
be formulated with a pharmaceutically acceptable carrier 
and, optionally one or more pharmaceutically acceptable 
excipients, for enteral or parenteral administration. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the anti-HDAC activity of arylhydantoin 
derived HDAC inhibitors 32-35 and 38-41 against HDACs 1, 
6 and 8 (IC50 in nM). 
FIG. 2 shows the anti proliferative activity of arylhydantoin 
derived HDAC inhibitors 32-35 and 38-41 against VCaP and 
DU-145 prostate cancer cell lines (IC50 in OM). 
FIGS. 3A-3B show antiproliferative assays were per-
formed on low passage cells for a 72 hour drug incubation 
period, and read using colorimetric assays with 0.4% DMSO 
control. *Greater than 50 µM 
FIG. 4 shows In vitro adrenergic receptor (AR) binding. 
The phenyl head group (Ary! Nil. HDACi) and the alkyl head 
group (Alkyl Nil. HDACi) with various linkers (n=3-8), and 
Cyano-Nilutamide, were tested by competiti?n against [.3 H] 
Mibolerone in vitro in cytosolic rat AR. The improved bmd-
ing with the Ary I cap group can be explained by Jt-Jt stacking 
with the AR surface and lower entropic penalties. 
DETAILED DESCRIPTION OF THE INVENTION 
I. Definitions 
AR represents an aryl group. "Ary!", as used herein, refers 
to - 6- and 7-membered aromatic, heterocyclic, fused aro-
matic, fused heterocyclic, biaromatic, or bihetereocyclic ring 
system, optionally substituted by halogens, alkyl-, alkeny.1-, 
and alkynyl-groups. Broadly defined, "AR", as used herem, 
includes 5-, 6- and 7-membered single-ring aromatic groups 
that may include from zero to four heteroatoms, for example, 
benzene, pyrrole, furan, thiophene, imidazole, oxazole, thia-
zole, triazole, pyrazole, pyridine, pyrazine, pyridazine and 
pyrimidine, and the like. Those aryl groups having heteroat-
oms in the ring structure may also be referred to as "aryl 
heterocycles" or "heteroaromatics". The aromatic ring can be 
Wherein: 
AR is an aryl group or a covalent bond; 
60 substituted at one or more ring positions with such substitu-
ents as described above, for example, halogen, alkyl, aralkyl, 
alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, 
sulfhydryl, imino, amido, carbonyl, carboxyl, silyl, ether, 
alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, het-
n consists ofC0 _6 group, optionally containing one or more 
heteroatoms, wherein the carbon atoms and/or heteroatoms 
are in a linear arrangement, 
65 erocyclyl, aromatic or heteroaromatic moieties, --:-C.F3 , 
--CN, or the like. The term "Ar" also includes polycyclic nng 
systems having two or more cyclic rings in which two or more 
US 9, 139,565 B2 
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carbons are connnon to two adjoining rings (the rings are 
"fused rings") wherein at least one of the rings is aromatic, 
e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, 
cycloalkynyls, aryls and/or heterocycles. Examples ofhetero-
cyclic ring include, but are not limited to, benzimidazolyl, 5 
benzofuranyl, benzothiofuranyl, benzothiophenyl, benzox-
azolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztet-
razolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, 
carbazolyl, 4aH carbazolyl, carbolinyl, chromanyl, chrome-
nyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazi- 10 
nyl, dihydrofuro [2,3b ]tetrahydrofuran, furanyl, furazanyl, 
imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, 
indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isati-
noyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindoli- 15 
nyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, meth-
ylenedioxyphenyl, morpholinyl, naphthyridinyl, 
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2, 
4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazo-
lidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, 20 
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, 
phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperi-
donyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, 
pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, 
pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, 25 
pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, 
pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinox-
alinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquino-
liny I, tetrahydroquinoliny I, tetrazoly I, 6H-1,2, 5-thiadiaziny I, 
1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3, 30 
4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiaz-
olyl, thienooxazolyl, thienoimidazolyl, thiophenyl and xan-
thenyl. 
The linking group A is chosen from amide, reverse amide, 35 
ester, reverse ester, alkoxyl, sulfanyl, sulfinyl, sulfonyl, sul-
fonamido, ketone, SP2 hybridized carbon, SP hybridized car-
bon, 5 or 6 membered heterocyclic rings including but not 
limiting to 1,2,3-triazolyl, 1,2,4-triazolyl, 1-tetrazolyl, 1-in-
dolyl, 1-indazolyl, 2-isoindolyl, 7-oxo-2-isoimdolyl, 1-piri- 40 
nyl, 3-isothiazolyl, 4-isothiazolyl and 5-isothiazolyl, 1,3,4,-
oxadiazole, 4-oxo-2-thiazolinyl, or 5-methyl-1,3,4-
thiadiazol-2-yl, thiazoledione, 1,2,3,4-thiatriazole, 1,2,4-
dithiazolone, pyridine, thiophene, furan, pyrazoline, 
pyrimidine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 45 
4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 
3-pyrazolyl, 2-quinolyl. 3-quinolyl, 1-isoquinolyl, 3-iso-
quinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 
2-quinoxalinyl, 1-phthalazinyl, 4-oxo-2-imidazolyl, 2-imi-
dazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isox- 50 
azolyl, 3-pyrazolyl 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 
4-oxazolyl, 4-oxo-2-oxazolyl, 5-oxazolyl, 4,5-dihydroox-
azole, 1,2,3-oxathiole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 
1,2,5-oxadiazole, 1,3,4-oxadiazole, 2-thiazolyl, 4-thiazolyl, 
55 5-thiazolyl, 3-isothiazole, 4-isothiazole, 5-isothiazole, 2-in-
dolyl, 3-indolyl, 3-indazolyl, 2-benzoxazolyl, 2-benzothiaz-
olyl, 2-benzimidazolyl, 2-benzofuranyl, 3-benzofuranyl, 
benzoisothiazole. benzisoxazole, 2-furanyl, 3-furanyl, 
2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 60 
4-isopyrrolyl, 5-isopyrrolyl, 1,2,3-oxathiazole-l-oxide, 1,2, 
4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 5-oxo-1,2,4-oxadia-
zol-3-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 3-oxo-
1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 2-oxo-1,3,4-
thiadiazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4- 65 
tetrazol-5-yl, 5-oxazolyl, 1-pyrrolyl, 1-pyrazolyl. Each of 
these moieties may be substituted as appropriate. 
6 
B is an alky I, alkylary I or alky lheteroary I spacer group. The 
alkyl spacer group chain length ranges from about cl to about 
C11 , optionally substituted by one or more double and/or 
triple bonds. 
"Zinc binding group" or "ZBG", as used herein, refers to 
moieties capable of inhibiting zinc metalloenzymes activity 
including HDAC and matrix metalloproteinase (MMP) activ-
ity. Suitable examples include, but are not limited to, hydrox-
amates, N-formyl hydroxylamine (or retro-hydroxamate), 
carboxylates, thiols, dithiols, trithiocarbonates, thioesters, 
benzamide, keto, mercaptoacetamides, 2-ketoamides, 
epoxides, epoxyketones, trifluoromethyl ketones, hydroxy-
pyridinones, pyrones, hydroxylpyridinethiones, and thiopy-
rones. 
"Alkyl", as used herein, refers to the radical of saturated or 
unsaturated aliphatic groups, including straight-chain alkyl, 
alkenyl, or alkynyl groups, branched-chain alkyl, alkenyl, or 
alkynyl groups, cycloalkyl, cycloalkenyl, or cycloalkynyl 
(alicyclic) groups, alkyl substituted cycloalkyl, cycloalkenyl, 
or cycloalkynyl groups, and cycloalkyl substituted alkyl, alk-
enyl, or alkynyl groups. Unless otherwise indicated, a straight 
chain or branched chain alkyl has 30 or fewer carbon atoms in 
its backbone. For example, Cl to C4 or C6 linear alkyl. 
Likewise, preferred cycloalkyls have from 3-10 carbon atoms 
in their ring structure, and more preferably have 5, 6 or 7 
carbons in the ring structure, and optionally contain or are 
substituted with heteroatoms, such as with 1, 2, 3 or more 
independently selected oxygen, nitrogen, or sulfur atoms. 
"Alkylaryl", as used herein, refers to an alkyl group sub-
stituted with an aryl group (e.g., an aromatic or hetero aro-
matic group). 
"Acy!" or "acyl group" as used herein is intended to mean 
a --C(O)-R radical, where R is a suitable substituent (for 
example, an acetyl group, a propionyl group, a butyroyl 
group, a benzoyl group, or an alkylbenzoyl group). 
"Heterocycle" or "heterocyclic", as used herein, refers to a 
cyclic radical attached via a ring carbon or nitrogen of a 
monocyclic or bicyclic ring containing 3-10 ring atoms, and 
preferably from 5-6 ring atoms, consisting of carbon and one 
to four heteroatoms each selected from the group consisting 
of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent 
or is H, 0, (C1_4 )alkyl, phenyl or benzyl, and optionally 
containing 1-3 double bonds and optionally substituted with 
one or more substituents. Examples of heterocyclic ring 
include, but are not limited to, benzimidazolyl, benzofuranyl, 
benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzox-
azolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, ben-
zisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 
4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnoli-
nyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydro-
furo [2,3-b ]tetrahydrofuran, furanyl, furazanyl, imidazolidi-
nyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, 
indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isoben-
zofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoin-
dolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenediox-
yphenyl, morpholinyl, naphthyridinyl, 
octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2, 
4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazo-
lidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, 
phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, 
phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperi-
donyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, 
pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, 
pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, 
pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, 
pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinox-
alinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquino-
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liny I, tetrahydroquinoliny I, tetrazoly I, 6H-1,2, 5-thiadiaziny I, 
1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3, 
4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiaz-
olyl, thienooxazolyl, thienoimidazolyl, thiophenyl and xan-
thenyl. 
"Heteroaryl", as used herein, refers to a monocyclic aro-
matic ring containing five or six ring atoms consisting of 
carbon and 1, 2, 3, or 4 heteroatoms each selected from the 
group consisting of non-peroxide oxygen, sulfur, and N(Y) 
where Y is absent or is H, 0, (C1 -C8 ) alkyl, phenyl or benzyl. 10 
Non-limiting examples of heteroaryl groups include fury!, 
imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, thiazolyl, 
isothiazoyl, pyrazolyl, pyrrolyl, pyrazinyl, tetrazolyl, 
pyridyl, (or its N-oxide ), thienyl, pyrimidinyl (or its N-oxide ), 15 
indolyl, isoquinolyl (or its N-oxide), quinolyl (or its N-oxide) 
and the like. The term "heteroaryl" can include radicals of an 
ortho-fused bicyclic heterocycle of about eight to ten ring 
atoms derived therefrom, particularly a benz-derivative or 
one derived by fusing a propylene, trimethylene, or tetram- 20 
ethylene diradical thereto. Examples of heteroaryl can be 
fury!, imidazolyl, triazolyl, triazinyl, oxazoyl, isoxazoyl, 
thiazolyl, isothiazoyl, pyraxolyl, pyrrolyl, pyrazinyl, tetra-
zolyl, pyridyl (or its N-oxide), thientyl, pyrimidinyl (or its 
N-oxide), indolyl, isoquinolyl (or its N-oxide), quinolyl (or 25 
its N-oxide), and the like. 
"Halogen", as used herein, refers to fluorine, chlorine, 
bromine, or iodine. 
The terms "alkenyl" and "alkynyl" refer to unsaturated 
aliphatic groups analogous in length and possible substitution 30 
to the alkyls described above, but that contain at least one 
double or triple bond respectively. 
The terms ortho, meta and para apply to 1,2-, 1,3- and 
1,4-disubstituted benzenes, respectively. For example, the 
names 1,2-dimethylbenzene and ortho-dimethylbenzene are 35 
synonymous. 
"Pharmaceutically acceptable salt", as used herein, refer to 
derivatives of the compounds defined by Formula I wherein 
the parent compound is modified by making acid or base salts 
thereof. Example of pharmaceutically acceptable salts 40 
include but are not limited to mineral or organic acid salts of 
basic residues such as amines; and alkali or organic salts of 
acidic residues such as carboxylic acids. The pharmaceuti-
cally acceptable salts include the conventional non-toxic salts 
8 
and Use," P. Heinrich Stahl and Camille G. Wermuth, Eds., 
Wiley-VCR, Weinheim, 2002. 
As generally used herein "pharmaceutically acceptable" 
refers to those compounds, materials, compositions, and/or 
dosage forms which are, within the scope of sound medical 
judgment, suitable for use in contact with the tissues of 
human beings and animals without excessive toxicity, irrita-
tion, allergic response, or other problems or complications 
commensurate with a reasonable benefit/risk ratio. 
"Prodrug", as used herein, refers to a pharmacological 
substance (drug) which is administered in an inactive (or 
significantly less active) form. Once administered, the pro-
drug is metabolized in the body (in vivo) into the active 
compound. 
"Solvate", as used herein, refers to a compound which is 
formed by the interaction of molecules of a solute with mol-
ecules of a solvent. 
"Reverse ester", as used herein, refers to interchange in the 
positions of the oxygen and carbon groups in a series of 
structurally related compounds. 
"Reverse amide", as used herein, refers to interchange in 
the positions of the nitrogen and carbon groups in a series of 
structurally related compounds. 
II. Compounds 
Compounds of Formula I, and methods of making and 
using thereof, are described herein. 
(I) 
x--r\-)--fR, )=I- )r--N'MAR-A-B-ZBG 
y w 
wherein: 
AR is an aryl group or is absent (i.e., represents a covalent 
bond); 
n consists of (or represents in conjunction with the struc-
ture shown in the associated parentheses, all of which can be 
replaced by a symbol or character such as B' as used below) a 
C0 _6 group, optionally containing one or more heteroatoms, 
wherein the carbon atoms and/or heteroatoms are in a linear 
arrangement (thus n can represent a covalent bond when C is 
0), 
A is a linking group connected to AR; 
Bis an alkyl, alkylaryl or alkylheteroaryl spacer group, 
ZBG is a Zinc Binding Group, 
or the quaternary ammonium salts of the parent compound 45 
formed, for example, from non-toxic inorganic or organic 
acids. Such conventional non-toxic salts include those 
derived from inorganic acids such as hydrochloric, hydrobro-
mic, sulfuric, sulfamic, phosphoric, and nitric acids; and the 
salts prepared from organic acids such as acetic, propionic, 50 
succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascor-
bic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, 
benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, 
toluenesulfonic, naphthalenesulfonic, methanesulfonic, 
ethane disulfonic, oxalic, and isethionic salts. 
The pharmaceutically acceptable salts of the compounds 
can be synthesized from the parent compound, which con-
tains a basic or acidic moiety, by conventional chemical meth-
ods. Generally, such salts can be prepared by reacting the free 
acid or base forms of these compounds with a stoichiometric 60 
amount of the appropriate base or acid in water or in an 
organic solvent, or in a mixture of the two; generally, non-
aqueous media like ether, ethyl acetate, ethanol, isopropanol, 
R1 and R2 are independently selected from groups consist-
55 ing of hydrogen, and/or together from groups comprising 1-8 
carbon atoms, selected from wherein these groups compris-
ing 1-8 carbon atoms are selected from groups consisting of 
alkyl, substituted alkyl including haloalkyl, and, together 
or acetonitrile are preferred. Lists of suitable salts are found in 
Remington's Pharmaceutical Sciences, 20th ed., Lippincott 
Williams & Wilkins, Baltimore, Md., 2000, p. 704; and 
"Handbook of Pharmaceutical Salts: Properties, Selection, 
with the carbon to which they are linked, a cycloalkyl or 
substituted cycloalkyl group, 
W is selected from the group consisting of 0 and S, 
X is selected from the group consisting of cyano and nitro, 
Y is selected from the group consisting oftrifluoromethyl 
65 and iodo. 
Thus particular examples of the foregoing include, but are 
not limited to, compounds of the Formulas Ia-Ik, as follows: 
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x-f\_)f~ )=I- )-N"-AR/A-B-ZBG 
y w 
(la) 
10 
(lb) 
15 
(le) 
20 
25 
10 
-continued 
(Ii) 
(Ij) 
(Ik) 
Where R' is acyl or alkyl; and where X, Y, W, Ru R2 , B' (or n), 
AR, A, B, and ZBG are all as given above or as given below. 
(Id) Examples of B', n, or the group represented by the struc-
(le) 
ture: 
30 
35 include, but are not limited to, a covalent bond, Cl to C6 
linear alkyl groups such as: --CH2-, --CH2 CH2-, 
--CH2 CH2CH2-, etc. 
Examples of group AR include, but are not limited to: 
40 
(If) 45 
50 
(lg) 
55 
(Ih) 60 
65 
11 
-continued 
F 
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The linking group A is chosen from amide, reverse amide, 
ester, reverse ester, alkoxyl, sulfanyl, sulfinyl, sulfonyl, sul-
fonamido, ketone, SP2 hybridized carbon, SP hybridized car-
25 bon, 5 or 6 membered heterocyclic rings including but not 
limiting to 1,2,3-triazolyl, 1,2,4-triazolyl, 1-tetrazolyl, 1-in-
dolyl, 1-indazolyl, 2-isoindolyl, 7-oxo-2-isoimdolyl, 1-piri-
nyl, 3-isothiazolyl, 4-isothiazolyl and 5-isothiazolyl, 1,3,4,-
30 oxadiazole, 4-oxo-2-thiazolinyl, or 5-methyl-1,3,4-
thiadiazol-2-yl, thiazoledione, 1,2,3,4-thiatriazole, 1,2,4-
dithiazolone, pyridine, thiophene, furan, pyrazoline, 
pyrimidine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 
4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 
35 3-pyrazolyl, 2-quinolyl. 3-quinolyl, 1-isoquinolyl, 3-iso-
quinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 
2-quinoxalinyl, 1-phthalazinyl, 4-oxo-2-imidazolyl, 2-imi-
dazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isox-
azolyl, 3-pyrazolyl 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 
40 4-oxazolyl, 4-oxo-2-oxazolyl, 5-oxazolyl, 4,5-dihydroox-
azole, 1,2,3-oxathiole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 
1,2,5-oxadiazole, 1,3,4-oxadiazole, 2-thiazolyl, 4-thiazolyl, 
5-thiazolyl, 3-isothiazole, 4-isothiazole, 5-isothiazole, 2-in-
dolyl, 3-indolyl, 3-indazolyl, 2-benzoxazolyl, 2-benzothiaz-
45 olyl, 2-benzimidazolyl, 2-benzofuranyl, 3-benzofuranyl, 
benzoisothiazole. benzisoxazole, 2-furanyl, 3-furanyl, 
2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 
4-isopyrrolyl, 5-isopyrrolyl, 1,2,3-oxathiazole-l-oxide, 1,2, 
4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-thiadiazol-5-
50 yl, 3-oxo-1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-5-yl, 2-oxo-
1,3,4-thiadiazol-5-yl, 1,2,4-triazol-5-yl, 5-oxazolyl, 
1-pyrrolyl, 1-pyrazolyl. Each of these moieties may be sub-
stituted as appropriate. Thus, examples oflinking groups "A" 
55 include, but are not limited to: 
60 
65 
US 9, 139,565 B2 
13 
where / indicates optional connecting points to A and B', or 
to A and the nitrogen atom of the hydantoin group when B' is 60 
absent. 
B is an alky 1, alky lary 1 or alky lheteroary 1 spacer group. The 
alkyl spacer group chain length ranges from about cl to about 
Cw optionally substituted by one or more double and/or 65 
triple bonds. Thus, examples of spacer groups "B" include, 
but are not limited to, Cl or C2 to C6 or CS linear alkyl, 
14 
optionally containing one or more double or triple bonds 
and/or -CH3 , -CH2CH3 branchings. 
"Zinc binding group" or "ZBG", as used herein, refers to 
moieties capable of inhibiting zinc metalloenzymes activity 
including HDAC and matrix metalloproteinase (MMP) activ-
ity. Suitable examples include, but are not limited to, hydrox-
amates, N-formyl hydroxylamine (or retro-hydroxamate), 
carboxylates, thiols, dithiols, trithiocarbonates, thioesters, 
benzamide, keto, mercaptoacetamides, 2-ketoamides, 
epoxides, epoxyketones, trifluoromethyl ketones, hydroxy-
pyridinones, pyrones, hydroxylpyridinethiones, and thiopy-
rones. Thus examples of zinc binding groups include, but are 
not limited to, the following: 
hydroxamic acids thiol-hydroxamic acids 
0 0 /()lN/0~0 /JlOR 
I 
R 
N-formyl hydroxylamines carboxylates 
where R is H, or alkyl such where R is Hor a salt 
nitro 
as methyl, ethyl, etc. colUlter ion such as Na+, etc 
thiols 
~s/8'-R 
dithiols 
R ~Acy! such as -COCH3 
or alkyl group such as methyl, 
ethyl, etc. 
mercaptoacetamides trithiocarbonates 
where R is Hor a salt 
colUlter ion such as Na+, etc 
thioesters 
R~Acylsuchas -COCH3 
or alkyl group such as methyl, 
ethyl, etc. 
benzamides epoxides 
~~; 
0 F 
epoxyketones trifluoromethyl ketones 
US 9, 139,565 B2 
15 
-continued 
0 
,;0R 
keto 2-ketoamides 
where R is an alkyl group where R, R' are independently 
such as methyl, ethyl, etc. Hor alkyl such as methyl or ethyl 
10 
Particular examples of active compounds of the present 
invention are set forth in Table 1 below. Additional examples 
of active compounds of the present invention include, but are 
15 
not limited to, the following: 
where R is H, methyl, or ethyl. 
10Jy~~'~" 
0 N S O 
A YCF3 
CN 
where R is Hor a salt colUlter ion (ex Na+, etc) 
40 
45 
50 
55 
60 
65 
16 
-continued 
~N~:c/"~" OAN~O 
A YCF3 
N02 
where R is acyl such as phenyl or alkyl such as methyl 
\_N(D--(~r~~if"'H OAN~O N 0 
A YCF3 
N02 
where R is H, methyl, or ethyl. 
where R is alkyl such as methyl or phenyl 
where Rand R' are independently Hor alkyl 
such as methyl or ethyl 
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where R is Hor a salt Counter ion (ex Na+, etc) 
(\/-(:I~ 0~As 0 
A YCl 
CN 
-LN~-<:r~SH 
OANAS 
A YCF3 
N02 
18 
where R is acyl or alkyl such as methyl or phenyl 
15 
III. Formulations and Administration 
20 Formulations containing one or more of the compounds 
described herein may be prepared using a pharmaceutically 
acceptable carrier composed of materials that are considered 
safe and effective and may be administered to an individual 
without causing undesirable biological side effects or 
25 unwanted interactions. The carrier is all components present 
in the pharmaceutical formulation other than the active ingre-
dient or ingredients. As generally used herein "carrier" 
includes, but is not limited to, diluents, binders, lubricants, 
disintegrators, fillers, pH modifying agents, preservatives, 
30 antioxidants, solubility enhancers, and coating compositions. 
Carrier also includes all components of the coating com-
position which may include plasticizers, pigments, colorants, 
stabilizing agents, and glidants. Delayed release, extended 
release, and/or pulsatile release dosage formulations may be 
35 prepared as described in standard references such as "Phar-
maceutical dosage form tablets", eds. Liberman et. al. (New 
York, Marcel Dekker, Inc., 1989), "Remington-The science 
and practice of pharmacy", 20th ed., Lippincott Williams & 
Wilkins, Baltimore, Md., 2000, and "Pharmaceutical dosage 
40 forms and drug delivery systems", 6th Edition, Ansel et al., 
(Media, Pa.: Williams and Wilkins, 1995). These references 
provide information on carriers, materials, equipment and 
process for preparing tablets and capsules and delayed release 
dosage forms of tablets, capsules, and granules. 
45 Examples of suitable coating materials include, but are not 
limited to, cellulose polymers such as cellulose acetate phtha-
late, hydroxypropyl cellulose, hydroxypropyl methylcellu-
lose, hydroxypropyl methylcellulose phthalate and hydrox-
ypropyl methylcellulose acetate succinate; polyvinyl acetate 
50 phthalate, acrylic acid polymers and copolymers, and meth-
acrylic resins that are commercially available under the trade 
name EUDRAGIT® (Roth Pharma, Westerstadt, Germany), 
zein, shellac, and polysaccharides. 
Additionally, the coating material may contain conven-
55 tional carriers such as plasticizers, pigments, colorants, 
glidants, stabilization agents, pore formers and surfactants. 
Optional pharmaceutically acceptable excipients present 
in the drug-containing tablets, beads, granules or particles 
include, but are not limited to, diluents, binders, lubricants, 
60 disintegrants, colorants, stabilizers, and surfactants. 
Diluents, also referred to as "fillers," are typically neces-
sary to increase the bulk of a solid dosage form so that a 
practical size is provided for compression of tablets or for-
mation of beads and granules. Suitable diluents include, but 
65 are not limited to, dicalcium phosphate dihydrate, calcium 
sulfate, lactose, sucrose, mannitol, sorbitol, cellulose, micro-
crystalline cellulose, kaolin, sodium chloride, dry starch, 
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hydrolyzed starches, pregelatinized starch, silicone dioxide, 
titanium oxide, magnesium aluminum silicate and powdered 
sugar. 
Binders are used to impart cohesive qualities to a solid 
dosage formulation, and thus ensure that a tablet or bead or 
granule remains intact after the formation of the dosage 
forms. Suitable binder materials include, but are not limited 
to, starch, pregelatinized starch, gelatin, sugars (including 
sucrose, glucose, dextrose, lactose and sorbitol), polyethyl-
ene glycol, waxes, natural and synthetic gums such as acacia, 
tragacanth, sodium alginate, cellulose, including hydrox-
ypropylmethylcellulose, hydroxypropylcellulose, ethylcellu-
lose, and veegum, and synthetic polymers such as acrylic acid 
and methacrylic acid copolymers, methacrylic acid copoly-
mers, methyl methacrylate copolymers, aminoalkyl meth-
acrylate copolymers, polyacrylic acid/polymethacrylic acid 
and polyvinylpyrrolidone. 
Lubricants are used to facilitate tablet manufacture. 
Examples of suitable lubricants include, but are not limited to, 
magnesium stearate, calcium stearate, stearic acid, glycerol 
behenate, polyethylene glycol, talc, and mineral oil. 
Disintegrants are used to facilitate dosage form disintegra-
tion or "breakup" after administration, and generally include, 
but are not limited to, starch, sodium starch glycolate, sodium 
carboxymethyl starch, sodium carboxymethylcellulose, 
hydroxypropyl cellulose, pregelatinized starch, clays, cellu-
lose, alginine, gums or cross linked polymers, such as cross-
linked PVP (Polyplasdone XL from GAF Chemical Corp). 
Stabilizers are used to inhibit or retard drug decomposition 
reactions which include, by way of example, oxidative reac-
tions. 
Surfactants may be anionic, cationic, amphoteric or non-
ionic surface active agents. Suitable anionic surfactants 
include, but are not limited to, those containing carboxylate, 
sulfonate and sulfate ions. Examples of anionic surfactants 
include sodium, potassium, ammonium of long chain alkyl 
sulfonates and alkyl aryl sulfonates such as sodium dodecyl-
benzene sulfonate; dialkyl sodium sulfosuccinates, such as 
sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuc-
cinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; 
and alkyl sulfates such as sodium lauryl sulfate. Cationic 
surfactants include, but are not limited to, quaternary ammo-
nium compounds such as benzalkonium chloride, benzetho-
nium chloride, cetrimonium bromide, stearyl dimethylbenzyl 
ammonium chloride, polyoxyethylene and coconut amine. 
Examples of nonionic surfactants include ethylene glycol 
monostearate, propylene glycol myristate, glyceryl 
monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbi-
tan acylate, sucrose acylate, PEG-150 laurate, PEG-400 
monolaurate, polyoxyethylene monolaurate, polysorbates, 
polyoxyethylene octylphenylether, PEG-1000 cetyl ether, 
polyoxyethylene tridecyl ether, polypropylene glycol butyl 
ether, Poloxamer® 401, steamy! monoisopropanolamide, 
and polyoxyethylene hydrogenated tallow amide. Examples 
of amphoteric surfactants include sodium N-dodecyl-.beta.-
alanine, sodium N-lauryl-.beta.-iminodipropionate, myristo-
amphoacetate, lauryl betaine and lauryl sulfobetaine. 
If desired, the tablets, beads, granules, or particles may also 
contain minor amount of nontoxic auxiliary substances such 
as wetting or emulsifying agents, dyes, pH buffering agents, 
or preservatives. 
The present invention is primarily concerned with the treat-
ment of human subjects, but the invention may also be carried 
out on animal subjects, particularly mammalian subjects such 
as dogs, cats, livestock and horses for veterinary purposes. 
20 
While subjects may be of any suitable age, the subjects are in 
some embodiments neonatal, infant, juvenile, adolescent, 
adult, or geriatric subjects. 
These compounds may be used as anti-cancer treatment for 
carcinomas, especially those found to express or over-express 
the androgen receptor or the GCPR6A receptor, which 
includes, but is not limited to breast cancers, pancreatic can-
cers and prostate cancers. They may also find use in treatment 
of other androgen-related conditions including, but not lim-
10 ited to, baldness, muscular dystrophy/atrophy, mental cogni-
tion, acne, substance abuse/addiction and behavioral disor-
ders. 
The therapeutically effective dosage of any specific com-
pound, will vary somewhat from compound to compound, 
15 and patient to patient, and will depend upon the condition of 
the patient and the route of delivery. As a general proposition, 
a dosage from about 0.1 to about 100 or 200 mg/kg may be 
used, with all weights being calculated based upon the weight 
of the active compound, including the cases where a salt is 
20 employed. Toxicity concerns at the higher level may restrict 
intravenous dosages to a lower level such as up to about 10 or 
20 mg/kg, with all weights being calculated based upon the 
weight of the active base, including the cases where a salt is 
employed. In some embodiments, a dosage from about 5 or 10 
25 mg/kg to about 50 or 100 mg/kg may be employed for oral 
administration. 
Other Active Agents. 
The arylhydantoin derived HDAC inhibitors described 
herein can be administered adjunctively with other active 
30 compounds. These compounds include but are not limited to 
analgesics, anti-inflammatory drugs, antipyretics, antidepres-
sants, antiepileptics, antihistamines, antimigraine drugs, anti-
muscarinics, anxioltyics, sedatives, hypnotics, antipsychot-
ics, bronchodilators, anti-asthma drugs, cardiovascular 
35 drugs, corticosteroids, dopaminergics, electrolytes, gastro-
intestinal drugs, muscle relaxants, nutritional agents, vita-
mins, parasympathomimetics, stimulants, anorectics and 
anti-narcoleptics. "Adjunctive administration", as used 
herein, means the inhibitors can be administered in the same 
40 dosage form or in separate dosage forms with one or more 
other active agents. 
Specific examples of compounds that can be adjunctively 
administered with the inhibitors include, but are not limited 
to, aceclofenac, acetaminophen, adomexetine, almotriptan, 
45 alprazolam, amantadine, amcinonide, aminocyclopropane, 
amitriptyline, amolodipine, amoxapine, amphetamine, arip-
iprazole, aspirin, atomoxetine, azasetron, azatadine, beclom-
ethasone, benactyzine, benoxaprofen, bermoprofen, 
betamethasone, bicifadine, bromocriptine, budesonide, 
50 buprenorphine, bupropion, buspirone, butorphanol, butrip-
tyline, caffeine, carbamazepine, carbidopa, carisoprodol, 
celecoxib, chlordiazepoxide, chlorpromazine, choline salicy-
late, citalopram, clomipramine, clonazepam, clonidine, 
clonitazene, clorazepate, clotiazepam, cloxazolam, clozap-
55 ine, codeine, corticosterone, cortisone, cyclobenzaprine, 
cyproheptadine, demexiptiline, desipramine, desomorphine, 
dexamethasone, dexanabinol, dextro amphetamine sulfate, 
dextromoramide, dextropropoxyphene, dezocine, diazepam, 
dibenzepin, diclofenac sodium, diflunisal, dihydrocodeine, 
60 dihydroergotamine, dihydromorphine, dimetacrine, dival-
proxex, dizatriptan, dolasetron, donepezil, dothiepin, dox-
epin, duloxetine, ergotamine, escitalopram, estazolam, etho-
suximide, etodolac, femoxetine, fenamates, fenoprofen, 
fentanyl, fludiazepam, fluoxetine, fluphenazine, flurazepam, 
65 flurbiprofen, flutazolam, fluvoxamine, frovatriptan, gabapen-
tin, galantamine, gepirone, ginko bilboa, granisetron, halo-
peridol, huperzine A, hydrocodone, hydrocortisone, hydro-
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(NMR) spectra were recorded on a Varian-Gemini 400 mag-
netic resonance spectrometer. 1 H NMR spectra were 
recorded in parts per million (ppm) relative to the peak of 
CDC13 , (7.24 ppm), CD3 0D (3.31 ppm), or DMSO-d6 (2.49 
ppm). 13C spectra were recorded relative to the central peak of 
the CDC13 triplet (77.0 ppm), CD30D (49.0 ppm), Acetone-
d6 septet (29.84 ppm) or the DMSO-d6 septet (39.7 ppm), and 
were recorded with complete hetero-decoupling. Multiplici-
morphone, hydroxyzine, ibuprofen, imipramine, indiplon, 
indomethacin, indoprofen, iprindole, ipsapirone, ketaserin, 
ketoprofen, ketorolac, lesopitron, levodopa, lipase, 
lofepramine, lorazepam, loxapine, maprotiline, mazindol, 
mefenamic acid, melatonin, melitracen, memantine, meperi-
dine, meprobamate, mesalamine, metapramine, metaxalone, 
methadone, methadone, methamphetamine, methocarbamol, 
methyldopa, methylphenidate, methylsalicylate, methyser-
gid( e ), metoclopramide, mianserin, mifepristone, milnacip-
ran, minaprine, mirtazapine, moclobemide, modafinil (an 
anti-narcoleptic), molindone, morphine, morphine hydro-
chloride, nabumetone, nadolol, naproxen, naratriptan, nefaz-
odone, neurontin, nomifensine, nortriptyline, olanzapine, 
olsalazine, ondansetron, opipramol, orphenadrine, oxafloz-
ane, oxaprazin, oxazepam, oxitriptan, oxycodone, oxymor-
phone, pancrelipase, parecoxib, paroxetine, pemoline, penta- 15 
zocine, pepsin, perphenazine, phenacetin, phendimetrazine, 
phenmetrazine, phenylbutazone, phenyloin, phosphati-
dylserine, pimozide, pirlindole, piroxicam, pizotifen, pizoty-
line, pramipexole, prednisolone, prednisone, pregabalin, pro-
10 ties are described using the abbreviations, singlet; d, doublet, 
panolol, propizepine, propoxyphene, protriptyline, 20 
quazepam, quinupramine, reboxitine, reserpine, risperidone, 
ritanserin, rivastigmine, rizatriptan, rofecoxib, ropinirole, 
rotigotine, salsalate, sertraline, sibutramine, sildenafil, sul-
fasalazine, sulindac, sumatriptan, tacrine, temazepam, tetra-
benozine, thiazides, thioridazine, thiothixene, tiapride, tia- 25 
s1p1rone, tizanidine, tofenacin, tolmetin, toloxatone, 
topiramate, tramadol, trazodone, triazolam, trifluoperazine, 
trimethobenzamide, trimipramine, tropisetron, valdecoxib, 
valproic acid, venlafaxine, viloxazine, vitamin E, zimeldine, 
ziprasidone, zolmitriptan, zolpidem, zopiclone and isomers, 30 
salts, and combinations thereof. 
EXAMPLES 
a-Bromoalkanoic acids and 7-bromoheptane nitrile were 
purchased from Sigma-Aldrich. Nuclear magnetic resonance 
Compound 
31 
t, triplet; q, quartet; m, multiplet; and app, apparent. High-
resolution mass spectra were recorded at the Georgia Institute 
of Technology mass spectrometry facility in Atlanta. Com-
mon reaction solvents were either high performance liquid 
chromatography (HPLC) grade or American Chemical Soci-
ety (ACS) grade, and used without further purification. "Pre-
parative TLC" or "prep TLC" refers to preparative thin layer 
chromatography and was performed onAnaltech preparative 
TLC plates (UV 254, 2000 µm), unless otherwise stated. 
"Column chromatography" or "flash column chromatogra-
phy" was performed with 200-400 Mesh silica gel, unless 
otherwise noted. UV light was used to examine the spots. 
Silica gel (200-400 Mesh) was used in column chromatogra-
phy. 
Compound numberings, e.g., 1, 2, 3, etc. as used in this 
example and method of preparation sections of the present 
application and entitled "Examples" and "IV. Methods of 
Preparation", are for reference within these sections only do 
not describe and are not to be confused with any similar 
numberings in other section of the present application. 
Compounds synthesized in accordance with the current 
invention are listed in Table 1. 
TABLE 1 
Structure 
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Compound Structure 
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Compound Structure 
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Compound Structure 
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IV. Methods of Preparation 
Example 1 
Synthesis of Compounds 31-42 
Scheme 1 below illustrates the synthesis of compounds 
31-42. 
35 
SCHEME 1 
HO~ TsCl ·~~ ii. -#~ # ~ 
2 
F ±NH 
±NH ¢l K1C03 0 NAO 0 NAO - ¢l i.NaH H CF3 CN CF3 
CN 
· · ¢f" TsCl · · ¢f" HO~, - Tso~' ii. 
0 
4 
28 
Cul, DIPEA, 
DMSO,rt,Ar 
0 
Br II 
'M'oR 
R~Et,n~3 
R~H,n ~4-9 
NaN3 
70' C. 
---
TFA:DCM (0.2:10)1 
TIPS(dropwise) 
29 
KOH,---- 6, R ~Et, n ~ 3 
L_____. 7,R~H,n~3 
8,R~H,n~4 
9,R~H,n~5 
10,R~H,n~6 
11,R~H,n~7 
12, R~ H, n ~ 8 
19, n ~3 
20, n ~4 
21, n ~5 
22, n ~ 6 
23, n ~ 7 
24, n ~ 8 
N --\__N/R-(l~J'N',OH 
O~N~O H 
A YCF3 
CN 
R'= 
31, n ~3 
32, n ~4 
33, n ~ 5 
34, n ~ 6 
35, n ~ 7 
36, n ~ 8 
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Coupling 
Reagent 
PANEL 1OF2 
25, n ~ 3 
26, n ~ 4 
27, n ~ 5 
28, n ~ 6 
29, n ~ 7 
30, n ~ 8 
PANEL 2 OF 2 
Trityl 
37, n ~ 3 
38, n ~ 4 
39, n ~ 5 
40, n ~ 6 
41,n ~ 7 
42, n ~ 8 
30 
0 
N3 ~ ,..o, ~N Trityl 
H 
13, n ~ 3 
14,n~4 
15, n ~ 5 
16, n ~ 6 
17, n ~ 7 
18, n ~ 8 
) 
Cul,DIPEA, 
DMSO,rt,Ar 
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were dissolved in 100 mL DCM, followed by addition of 
catalytic 4-dimethylaminopyridine. Reaction stirred for 48 
hours at ambient temperature, then solution was washed with 
200 mL H20, 150 mL saturated aqueous NH4 Cl, and lastly \J_NH 
OANAO 
A YCF3 
5 150 mL brine. Organic layer was dried over sodium sulfate, 
filtered and concentrated in vacuo. Column chromatography 
(eluent 12: 1 hexanes/EtOAc) gave 3 as a clear liquid (6.95 g, 
90%). 1H NMR (400 MHz, CDC13 ) ll 1.37-1.60 (2H, m), 
1.61-1.81 (2H, m), 1.89 (lH, s), 2.10 (2H, t, 1=5.5 Hz), 2.39 
10 (3H, s), 4.00 (2H, t, J=6.1 Hz), 7.30 (2H, d, J=7.8 Hz), 7.73 
(2H, d, J=7.9 Hz) ppm. 
CN 
15 
Procedure for synthesis of cyano-nilutamide (1) 
(Cogan, P. S.; Koch, T. H. Rational Design and Synthesis of 
Androgen Receptor-Targeted Nonsteroidal Anti-Androgen 
Ligands for the Tumor-Specific Delivery of a Doxorubicin- 20 
Formaldehyde Conjugate. J. Med. Chem. 2003, 46, 5258-
5270) 4-Fluoro-2-(trifluoromethyl)benzonitrile ( 4.02 g, 21.3 
mmol) was added to Hydantoin (13.6 g, 106.3 mmol) and 
Potassium Carbonate ( 4.40 g, 31.9 mmol) in 60 mL DMF and 
stirred at 45° C. under argon for 48 hours. Reaction mixture 25 
was then diluted in ethyl acetate and washed three times with 
water. Organic layer was dried over sodium sulfate, filtered 
and concentrated in vacuo. Colunm chromatography (eluent 
30:1 DCM/Methanol) gave 1 as a white solid (4.62 g, 74%). 
1H NMR (400 MHz, (CD3 ) 2--CO) ll 1.54 (6H, s), 7.80 (lH, 30 
s), 8.13 (lH, dd, J=l.8 Hz, J=8.4 Hz), 8.20 (lH, d, J=8.4 Hz), 
8.26 (lH, d, J=l.8 Hz) 
TsOl() 
~ 
Procedure for Conversion of 4-Ethynylbenzyl 
Alcohol into 4-Ethynylbenzyl tosylate (2) 
2 
35 
40 
4-Ethynylbenzyl alcohol (2.59 g, 19.59 mmol) was dis- 45 
solved in 200 mL THF. Potassium hydroxide (11.0 g, 195.9 
mmol) and tosylchloride (11.2 g, 58.8 mmol) were added 
while stirring, and reacted for 12 hours at ambient tempera-
ture. Solids were then filtered off, and solution was concen-
trated in vacuo. Colunm chromatography ( eluent 10: 1 hex- 50 
anes/EtOAc ), followed by recrystallization in hexane/EtOAc 
gave2 as an off white solid(2.74 g, 49%). 1HNMR (CDC13 , 
400 MHz) ll 2.37 (3H, s), 3.11 (lH, s), 5.00 (2H, s), 7.16 (2H, 
d, J=8.0), 7.28 (2H, d, J=8.0), 7.37 (2H, d, J=8.0), 7.74 (2H, 
\j___j < ) 
OANAO 
A YCF3 
CN 
Representative Procedure for Synthesis of Cyano-
Nilutamide-Alkynes. 4-[3-[ ( 4-ethyny lpheny l)me-
thy l]-4,4-dimethy l-2,5-dioxo- l -imidazolidinyl ]-2-
(trifluoromethyl)-benzonitrile ( 4) 
4 
Compound 1 (565.2 mg, 1.90 mmol) was dissolved in 7 mL 
DMF under argon, followed by addition of NaH (60% in 
mineral oil, 129.3 mg, 3.23 mmol) and stirring for 2 hours at 
ambient temperature. Then 2 (1,089 mg, 3.80 mmol) was 
added and reaction was stirred for 11 hours at 53 ° C. Mixture 
was then dissolved in 100mL3:1 EtOAc/hexanes and washed 
3 times with 150 mL brine. Organic layer was dried over 
sodium sulfate, filtered and concentrated in vacuo. Column d, J=8.0). 
TsO~ 
55 chromatography (eluent 3:1 hexanes/EtOAc) gave 4 as a 
white solid (537.9 mg, 69%). 1H NMR (400 MHz, CDC13 ) ll 
1.3 7 ( 6H, s ), 3 .09 (1 H, s ), 4.57 (2H, s ), 7 .30 (2H, d, J=8.4 Hz), 
7.41 (2H, d, J=8.3 Hz), 7.86 (lH, d, J=8.4 Hz), 8.00 (lH, dd, 
J=l.9, 8.4 Hz), 8.14 (lH, d, J=7.3 Hz) ppm. 
Procedure for Conversion of 5-Hexynyl alcohol into 
5-Hexynyl tosylate (3) 
5-Hexynyl alcohol (3.00 g, 30.6 mmol), triethylamine 
( 4.64 g, 45.8 mmol) and tosylchloride (8.74 g, 45.8 mmol) 
60 
4-[3-( 4-ethynylbutyl)-4,4-dimethyl-2,5-dioxo- l-
imidazolidinyl]-2-(trifluoromethyl)benzonitrile (5) 
Reaction of 1 (1.00 g, 3.364 mmol) with NaH and then 3 
65 (1.697 g, 6.728 mmol) as described for the synthesis of 4, 
followed by colunm chromatography (eluent 3:1 hexanes/ 
EtOAc) gave 4 as a white solid (1.154 g, 90% ). 1 H NMR ( 400 
US 9, 139,565 B2 
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MHz, cdcl3) o 1.50 (SH, s), 1.52-1.63 (2H, m), 1.67-1.85 (2H, 
m), 1.88-2.02 (lH, m), 2.05-2.33 (2H, m), 3.18-3.46 (2H, m), 
7.87 (lH, d, 1=8.4 Hz), 7.97 (lH, dd, 1=1.8, 8.4 Hz), 8.11 (lH, 
d, l=l.5 Hz) ppm. 
0 
Br II ~OR 
R~Et,n~3 
R~H,n~4-9 
NaN3 
70° c. 
-
KOHC 6, R ~Et, n ~ 3 
7,R~H,n~3 
8, R~H,n~4 
9, R~H,n~5 
10,R~H,n~6 
11,R~H,n~7 
12,R~H,n~ 8 
Representative Procedure for Synthesis of 
w-Azidoalkanoic Acids. 4-Azidobutanoic acid (7) 
Ethyl 4-bromobutanoate (17.11 g, 87.7 mmol) and NaN3 
(28.50 g, 438.5 mmol) was dissolved in 70 mL DMF and 
reacted at 77° C. for 30 hours. 250 mL of 4: 1 EtOAc/hexanes 
was added, and was washed twice with 250 mL saturated 
aqueous sodium bicarbonate, and once with 200 mL water. 
Organic layer was dried over sodium sulfate, filtered and 
concentrated in vacuo to give ethyl 4-azidobutanoate 6 (13.26 
10 
15 
34 
0 
N30 /O'-. 
n 1i Trityl 
13, n~ 3 
14, n ~ 4 
15, n~ 5 
16, n~ 6 
17, n ~ 7 
18, n~ 8 
Procedure for Conversion of 4-Azidobutanoic Acid 
to 4-Azido-0-tritylbutylhydroxamate (13) 
4-azidobutanoicacid 7 (1.01 g, 7.843 mmol), TBTU(4.197 
g, 13.07 mmol) and diisopropylethylamine (1.689 g, 13.07 
mmol) were added to 100 mL DCM at ambient temperature. 
20 0-tritylhydroxylamine (1.80 g, 6.536 mmol) was added last, 
and reaction stirred for 10 hours. Solvent was removed in 
vacuo, and colunm chromatography (eluent 4:1 hexanes/ 
EtOAc) gave 13 as a clear semi-solid (2.53 g, 91.2%). 1H 
NMR ( 400 MHz, cdcl3) o 1.42-1.61 (2H, m), 1.60-1.80 (2H, 
25 m), 2.86-3.18 (2H, m), 7.21-7.61 (15H, m), 7.78 (lH, s)ppm. 
g, 96%). Ethyl 4-azidobutanoate 6 (6.18 g, 39.29 mmol) was 
then saponified using excess KOH in 12: 10 methanol/water at 30 
0° C. for 5 minutes and then ambient temperature for 11 
hours, followed by acid workup to yield 4-Azidobutanoic 
acid 7 (4.69 g, 92%). 1H NMR (400 MHz, cdcl3) o 1.71-1.98 
(2H, m), 2.45 (2H, t, 1=7.2 Hz), 3.35 (2H, t, 1=6.7 Hz), 11.21 
(lH, s) ppm. 35 
Representative procedure for conversion of 
w-azidoalkanoic acids to 0-trityl hydroxamates. 
5-Azido-0-tritylpentahydroxamate (14) 
5-azidopentanoic acid la (1.1 g, 7 .69 mmol) was dissolved 
in anhydrous THF. N-methylmorpholine (0.84 mL, 7.69 
mmol) was added to the solution. The reaction mixture was 
then cooled down to -15° C. and stirred for 5 min. Isobutyl-
chloroformate (1.00, 7.69 mmol) was added and the mixture 
was stirred for 10 minat-15° C. 0-tritylhydroxylamine (2.11 
5-Azidopentanoic acid (8) 
Reaction of 5-bromopentanoic acid and NaN3 , as 
described for the synthesis of 6, gave 5-azidobutanoic acid 8. 
Saponification was not necessary. Used without further puri-
fication. 
6-Azidohexanoic acid (9) 
Reaction of 6-bromohexanoic acid and NaN3 , as described 
for the synthesis of 6, gave 6-Azidohexanoic acid 9. Saponi-
fication was not necessary. Used without further purification. 
7-Azidoheptanoic acid (10) 
Reaction of 7-bromoheptanoic acid and NaN3 , as 
described for the synthesis of 6, gave 5-azidoheptanoic acid 
10. Saponification was not necessary. Used without further 
purification. 
8-Azidooctanoic Acid (11) 
g, 7 .69 mmol) was added followed by 2 more equivalents of 
N-methylmorpholine. Stirring continued for 15 min at -15° 
C. and 2 h at room temperature. Afterwards the mixture was 
40 poured into 2M HCl and extracted 3 times in each case with 
water, sodium bicarbonate solution (5%) and water. After 
washing with brine and drying over Na2 S04 , solvent was 
evaporated in vacuo to yield 2.78 mg (90%) of 14 as a white 
solid with no further purification required. 1 H NMR (D MS0-
45 d6 , 400 MHz) o 1.17-1.25 (4H, m), 1.79 (2H, t, 1=5.8 Hz), 
3.15 (2H, t, 1=6.l Hz), 7.27-7.31 (15H, m), 10.22 (lH, s); 13C 
NMR(CDC13 , lOOMHz) o 20.1, 27.7, 30.1, 50.6, 93.0, 127.8, 
128.6, 140.6, 176.0. 
50 6-Azido-0-tritylhexahydroxamate (15) 
(As described in Mwakwari, S.C.; Guerrant, W.; Patil, V.; 
Khan, S. I.; Tekwani, B. L.; Gurard-Levin, Z. A.; Mrksich, 
M.; Oyelere, A. K. Nonpeptide Macrocyclic Histone 
55 Deacetylase (HDAC) Inhibitors Derived from Tricyclic 
Ketolide. J. Med. Chem. 2010, 53, 6100-6111) 
7-Azido-0-tritylheptahydroxamate (16) 
Reaction of 8-bromooctanoic acid and NaN3 , as described 
for the synthesis of 6, gave 8-azidooctanoic acid 11. Saponi- 60 
fication was not necessary. Used without further purification. 
Reaction of7-azidoheptanoic acid 10 ( 434 mg, 2.54 mmol) 
and 0-tritylhydroxylamine (700 mg, 2.545 mmol) as 
described for the synthesis of 14, followed by flash chroma-
tography (eluent 2:1 hexanes/EtOAc) gave 837 mg (77%) of 
16 as a white solid. 1H NMR (DMSO-d6 , 400 MHz) o 0.94-
1.01 (2H, m), 1.06-1.19 ( 4H, m), 1.71-1.78 ( 4H, m), 3.59 (lH, 
s), 4.34 (2H, t, 1=8), 7.25-7.36 (16H, m), 7.44-7.47 (lH, m), 
8.07 (lH, s), 8.17-8.20 (lH, m), 8.51-8.52 (lH, m), 8.68 (lH, 
9-Azidononanoic Acid (12) 
Reactionof9-bromononanoic acidandNaN3 , as described 65 
for the synthesis of 6, gave 5-azidobutanoic acid 12. Saponi-
fication was not necessary. Used without further purification. 
US 9, 139,565 B2 
35 
s), 9.03-9.04 (lH, m), 10.16 (lH, s); 13C NMR (CDC13 , 100 
MHz) ll 25.8, 29.7, 30.7, 46.9, 50.1, 53.8, 93.1, 119.8, 123.5, 
126.6, 127.7, 128.4, 128.8, 132.7, 144.0, 144.4, 146.7, 148.9, 
176.8. 
36 
a white solid(216mg, 76%). 1HNMR(400MHz, DMSO-d6 ) 
ll 1.39 (6H, s), 1.69-1.90 (4H, m), 4.00-4.17 (2H, m), 4.63 
(2H, s), 7.22-7.43 (15H, m), 7.50 (2H, d, 1=8.1 Hz), 7.78 (2H, 
d, 1=8.1 Hz), 8.09 (lH, d, 1=8.4 Hz), 8.24 (lH, s), 8.32 (lH, 
5 d, 1=8.4 Hz), 8.37 (lH, s), 10.30 (lH, s) ppm. 
8-Azido-0-trityloctahydroxamate (17) 
Reaction of 8-azidooctanoic acid 11 (1.71 g, 9.21 mmol) 
and 0-tritylhydroxylamine (2.55 g, 9.27 mmol) as described 
for the synthesis of 14, followed by flash chromatography 10 
( eluent 2: 1 hexanes/EtOAc) gave 2.59 g (88%) of 17 as a 
white solid. 1 H NMR (CDC13 , 400 MHz) ll 0.88-1.39 (SH, m), 
1.39-1.54 (4H, m), 3.12 (2H, t, 1=6.9 Hz), 7.10-7.49 (15H, 
m), 7.67 (lH, s); 13C NMR (CDC13 , 100 MHz) ll 23.2, 24.9, 15 26.4, 28.7, 31.1, 33.2, 51.3, 93.1, 127.1, 128.0, 128.9, 141.0, 
141.8, 146.8, 177.1. 
9-Azido-0-tritylnonahydroxamate (18) 
Reaction of9-azidononanoic acid 12 (724 mg, 3.63 mmol) 
and 0-tritylhydroxylamine (1.00 g, 3.63 mmol) overnight as 
described for the synthesis of 14, followed by flash chroma-
tography ( eluent 2: 1 hexanes/EtOAc) gave 940 mg (56%) of 
20 
18 as a sticky white solid. 1 H NMR (CDC13 , 400 MHz) ll 1.26 25 (lOH,m), 1.57 (4H, m), 3.24 (2H, t, 1=6.8 Hz), 7.34 (15H,m), 
7.74 (lH, s). 
0-trity 1-cyanonilutamide-benzy 1-triazoly lpentahy-
droxamate (20) 
Reaction of 4 and 14 as described for 19 gave the product 
20 in 41 % yield. 1 H NMR ( 400 MHz, CDC13 ) ll 1.24 (2H, s ), 
1.41 (6H, s), 1.49-1.75 (4H, m), 4.13-4.26 (2H, m), 4.63 (2H, 
s), 7.15-7.49 (15H, m), 7.41 (2H, d, 1=8.0 Hz), 7.74 (lH, s), 
7.79 (2H, d, 1=7.9 Hz), 7.89 (lH, d, 1=8.4 Hz), 8.03 (lH, dd, 
l=l.7, 8.5 Hz), 8.19 (lH, d, 1=1.4 Hz) ppm. 
0-trityl-cyanonilutamide-benzyl-triazolylhexahy-
droxamate (21) 
Reaction of 4 and 15 as described for 19 gave the product 
21 in 98% yield. 1H NMR (400 MHz, CDC13 ) ll 0.91-1.15 
(2H, m), 1.18-1.33 (2H, m), 1.40 (6H, s), 1.50-1.63 (2H, m), 
1.66-1.81 (3H, m), 4.18-4.33 (2H, m), 4.63 (2H, s), 7.34 
(15H, dd, 1=9.1, 55.1 Hz), 7.41 (2H, d, 1=7.2 Hz), 7.76 (lH, 
s), 7.80 (2H, d, 1=8.1 Hz), 7.83 (lH, s), 7.88 (lH, d, 1=8.4 Hz), 
8.02 (lH, dd, 1=1.7, 8.4 Hz), 8.18 (lH, d, l=l.6 Hz) ppm. 
0-trity 1-cyanonilutamide-benzy 1-triazoly lheptahy-
30 droxamate (22) 
R'~ 19, n ~3 
20, n ~4 
21, n ~s 
22, n ~ 6 
23, n ~ 7 
24, n ~ 8 
25, n ~ 3 
26, n ~ 4 
27, n ~ 5 
28, n ~ 6 
29, n ~ 7 
30, n ~ 8 
Representative procedure for Cu(I)-catalyzed 
cycloaddition reaction. 0-trityl-cyanonilutamide-
benzy 1-triazoly lbuty lhydroxamate (19) 
Reaction of 4 and 16 as described for 19 gave the product 
22 in 82% yield. 1H NMR (400 MHz, CDC13 ) ll 0.97-1.32 
(6H, m), 1.42 (6H, s), 1.75-1.95 (4H, m), 4.32 (2H, s), 4.64 
35 (2H, s), 7.35 (15H, dd, 1=14.2, 54.1 Hz), 7.42 (2H, d, 1=8.1 
Hz), 7.74 (lH, s), 7.81 (2H, d, 1=8.1 Hz), 7.90 (lH, d, 1=8.5 
Hz), 8.04 (lH, dd, 1=1.8, 8.4 Hz), 8.19 (lH, s) ppm. 
40 
0-trityl-cyanonilutamide-benzyl-triazolyloctahy-
droxamate (23) 
Reaction of 4 and 17 as described for 19 gave the product 
23 in 92% yield. 1 H NMR (CDC13 , 400 MHz) ll 1.03 (2H, m), 
45 
1.23 (6H, m), 1.42 (6H, s), 1.56 (2H, m), 1.87 (2H, m), 4.35 
(2H, t, 1=7.1), 4.65 (2H, s), 7.32 (15H, m), 7.42 (2H, d, 1=8.2), 
7.61 (lH, s), 7.76 (lH, s), 7.82 (2H, d, 1=8.2), 7.91 (lH, d, 
1=8.4), 8.04 (lH, dd, 1=1.8, 8.4), 8.19 (lH, d, 1=1.7). 
50 0-trityl-cyanonilutamide-benzyl-triazolylnonahy-
droxamate (24) 
Reaction of 4 and 18 as described for 19 gave the product 
24 in 87% yield. 1H NMR (300 MHz, CDC13 ) 0.88-1.34 
55 (llH,m), 1.42 (6H, s), 1.47-1.65 (2H,m), 1.74-1.95 (3H,m), 
4.35 (2H, t, 1=7.l Hz), 4.64 (2H, s), 7.35 (15H, dd, 1=12.0, 
40.9 Hz), 7.42 (2H, d, 1=8.4 Hz), 7.77 (lH, s), 7.82 (2H, d, 
1=8.3 Hz), 7.90 (lH, d, 1=8.5 Hz), 8.04 (lH, dd, 1=2.0, 8.4 
Hz), 8.19 (lH, d, 1=2.0 Hz) ppm. 
4-[3-[(4-ethynylphenyl)methyl]-4,4-dimethyl-2,5-dioxo-
l-imidazolidinyl]-2-(trifluoromethyl)-benzonitrile 4 (147.3 
mg, 0.358 mmol), 4-azido-0-tritylbutylhydroxamate 13 (167 
mg, 0.430 mmol) and DIPEA (94.35 mg, 0.730 mmol) were 
added to 2.55 mL anhydrous DMSO under argon. Copper(!) 60 
iodide (34.8 mg, 0.183 mmol) was then added, and reaction 
stirred under argon at ambient temperature overnight. The 
reaction mixture was diluted with DCM (30 mL) and washed 
with 1:4 NH4 0H/saturated NH4 Cl (3x30 mL) and saturated 
NH4 Cl (30 mL), and organic layer was dried over sodium 65 
sulfate, filtered and concentrated in vacuo. Column chroma-
tography ( eluent 80:4: 1 DCM/ Acetone/Methanol) gave 19 as 
0-trity 1-cyanonilutamide-buty 1-triazoly lbutylhydrox-
amate (25) 
Reaction of 5 and 13 as described for 19 gave the product 
25 in 87% yield. 1 11 NMR (400 MHz, DMSO-d6 ) 1.43 (6H, 
s), 1.58-1.73 (6H, m), 1.73-1.85 (2H, m), 2.62 (2H, t, 1=6.9 
Hz), 3.99 (2H, t, 1=6.8 Hz), 7.10-7.40 (15H, m), 7.66 (lH, s), 
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S.01 (lH, dd, 1=2.0, S.4 Hz), S.17 (lH, d, l=l .S Hz), S.2S (lH, 
d, l=S.4 Hz), 10.29 (lH, s) ppm. 
0-trity 1-cyanonilutamide-buty 1-triazoly lpentahy-
droxamate (26) 
Reaction of 5 and 14 as described for 19 gave the product 
10 
26 in 93% yield. 1 H NMR ( 400 MHz, CDC13 ) ll 1.15-1.29 
(2H, m), 1.50 (6H, s), 1.52-1.67 (4H, m), 1.69-1.SO (4H, m), 
2.75 (2H, t, 1=6.S Hz), 3.37 (2H, t, 1=7.2 Hz), 4.13 (2H, t, 
1=6.7 Hz), 7.24 (lH, s), 7.25-7.50 (15H, m), 7.7S (lH, s), 7.SS 
(lH, d, l=S.4 Hz), 7.9S (lH, dd, 1=1.9, S.5 Hz), S.14 (lH, d, 15 
l=l.7 Hz) ppm. 
0-trity 1-cyanonilutamide-buty 1-triazolylhexahydrox-
amate (27) 
Reaction of 5 and 15 as described for 19 gave the product 
20 
27 in S4% yield. 1H NMR (400 MHz, CDC13 ) ll 0.93-1.16 
(2H, m), 1.lS-1.33 (2H, m), 1.50 (6H, s), 1.63-1.95 (SH, m), 25 
2.72-2.79 (2H, m), 3.32-3.41 (2H, m), 4.20 (2H, t, 1=7.l Hz), 
7.14-7.53 (15H, m), 7.77 (lH, s), 7.S7 (lH, d, l=S.5 Hz), 7.9S 
(lH, dd, 1=1.7, S.5 Hz), S.14 (lH, d, 1=1.7 Hz) ppm. 
R'~ 31, n~ 3 
32, n ~ 4 
33, n ~ 5 
34, n ~ 6 
35, n ~ 7 
36, n ~ 8 
38 
37, n ~ 3 
38, n ~ 4 
39, n ~ 5 
40, n ~ 6 
41, n~ 7 
42, n ~ 8 
Representative Procedure for Deprotection of 0-Tri-
tyl-Hydroxamates. 0-trityl-cyanonilutamide-benzyl-
triazolylbutylhydroxamic acid (31) 
0-trityl-cyanonilutamide-benzy 1-triazoly lbuty lhydrox-
amate 19 (195 mg, 0.243 mmol) was dissolved in 9.1 mL of 
30 DCM and 0.2 mL triisopropylsilane at ambient temperature. 
0-trity 1-cyanonilutamide-buty 1-triazoly lheptahy-
droxamate (2S) 
Reaction of 5 and 16 as described for 19 gave the product 
2S in S2% yield. 1 H NMR ( 400 MHz, DMSO-d6 ) ll O.S7-0.97 
(2H, m), 0.97-1.07 (2H, m), 1.0S-1.lS (2H, m), 1.42 (6H, s), 
1.55-1.69 (6H, m), 1.73 (2H, t, 1=7.2 Hz), 2.57-2.6S (2H, m), 
3.27-3.36 (2H, m), 4.20 (2H, t, 1=7.l Hz), 7.lS-7.39 (15H, 
m), 7.Sl (lH, s), S.01 (lH, dd, 1=2.0, S.4 Hz), S.17 (lH, d, 
l=l.7 Hz), S.2S (lH, d, l=S.4 Hz), 10.15 (lH, s) ppm. 
0-trity 1-cyanonilutamide-buty 1-triazolyloctahydrox-
amate (29) 
Trifluoroacetic acid (O.lS mL) was added, and then triisopro-
pylsilane was added dropwise until solution turned from yel-
low to clear, and reaction was stirred for 5 minutes. Solvent 
and trifluoroacetic acid were removed in vacuo, and residue 
35 was washed with 10 mL of petroleum ether. Preperative TLC 
( eluent 37:1 acetonitile/water) provided 96 mg (71 % ) of31 as 
a light yellow semisolid. 1H NMR (DMSO-d6 , 400 MHz) ll 
1.3S (6H, s), 1.S5-2.19 (4H, m), 4.27-4.49 (2H, m), 4.62 (2H, 
s), 7.50 (2H, d, 1=7.2 Hz), 7.SO (2H, d, 1=6.S Hz), S.OS (lH, 
40 d, 1=7.1 Hz), S.23 (lH, s), S.30 (lH, d, 1=7.0 Hz), S.57 (lH, 
s), 10.52 (lH, s) ppm. 
45 
0-trity 1-cyanonilutamide-benzy 1-triazoly lpentahy-
droxamic acid (32) 
Reaction of 20 with trifluoroacetic acid as described for 31 
gave the product 32 in 63% yield. HRMS (MALDI) calcu-
lated for [C27H26F3 N7 0 4 +Ht570.2032. found 570.21. 
Reaction of 5 and 17 as described for 19 gave the product 50 
29 in 92% yield. 1 H NMR (CDC13 , 400 MHz) ll 1.0S (SH, m), 
1.49 (6H, s), 1.54 (2H, m), 1.77 (6H, m), 2.75 (2H, s), 3.37 
(2H, s), 4.25 (2H, t, 1=7.17, 7.17), 7.31 (15H, s), 7.61 (lH, s), 
7.76 (lH, s), 7.S7 (lH, d, l=S.4), 7.97 (lH, dd, l=l.S, S.4), 
0-trity 1-cyanonilutamide-benzy 1-triazoly lheptahy-
droxamic acid (33) 
Reaction of 21 with trifluoroacetic acid as described for 31 
gave the product 33 in 16% yield. HRMS (MALDI) calcu-
lated for [C28H28F3 N7 0 4 +Ht5S4.21SS. found 5S4.2217. S.13 (lH, d, 1=1.5). 55 0-trityl-cyanonilutamide-benzyl-triazolylhexahy-
droxamic acid (34) 
0-trity 1-cyanonilutamide-buty 1-triazoly lnonahydrox-
amate (30) 
Reaction of 22 with trifluoroacetic acid as described for 31 
60 
gave the product 34 in 67% yield. HRMS (MALDI) calcu-
lated for [C29H30F3 N7 0 4 +Ht59S.2345. found 59S.2395. 
Reaction of 5 and 1 S as described for 19 gave the product 
30 in 95% yield. 1H NMR (300 MHz, CDC13 ) ll 0.91-1.42 
(12H, m), 1.49 (6H, s), 1.67-1.S7 (6H, m), 2.75 (2H, s), 3.36 
(2H, s), 4.26 (2H, t, 1=7.l Hz), 7.30 (15H, s), 7.76 (lH, s), 65 
7.S6 (lH, d, l=S.4 Hz), 7.9S (lH, dd, 1=1.7, S.4 Hz), S.13 (lH, 
d, l=l.2 Hz) ppm. 
0-trity 1-cyanonilutamide-benzy 1-triazoly lheptahy-
droxamic acid (35) 
Reaction of 23 with trifluoroacetic acid as described for 31 
gave the product 35 in 35% yield. HRMS (MALDI) calcu-
lated for [C30H32F3 N7 0 4 +Ht612.2501. found 612.2524. 
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0-trityl-cyanonilutamide-benzyl-triazolyloctahy-
droxamic acid (36) 
40 
0-trityl-cyanonilutamide-butyl-triazolylhexhydrox-
amic acid (40) 
Reaction of 24 with trifluoroacetic acid as described for 31 
gave the product 36 in 92% yield. 1 H NMR ( 400 MHz, 5 
CDC13 ) ll 0.63-1.32 (!OH, m), 1.39 (6H, s), 1.45-1.68 (2H, 
m), 1.72-2.00 (2H, m), 4.34 (2H, bs), 4.60 (2H, s), 7.39 (2H, 
bs), 7.68-7.84 (2H, m), 7.90 (lH, d, J=6.4 Hz), 7.99 (lH, d, 
1=6.7 Hz), 8.13 (lH, s) ppm. 
Reaction of 28 with trifluoroacetic acid as described for 31 
gave the product 40 in 38% yield. HRMS (MALDI) calcu-
lated for [C26H32F3 N7 0 4 +Ht564.2501. found 564.2596. 
0-trityl-cyanonilutamide-butyl-triazolylbutylhydrox-
amic acid (37) 
Reaction of 25 with trifluoroacetic acid as described for 31 
gave the product 37 in 100% yield. 1H NMR (400 MHz, 
DMSO-d6 ) ll 1.32-1.52 (6H, m), 1.65 (4H, s), 1.97 (4H, s), 
2.65 (2H, s), 3.34 (2H, s), 4.29 (2H, d, J=6.1 Hz), 7.86 (lH, s), 
8.03 (lH, d, J=8.2 Hz), 8.18 (lH, s), 8.30 (lH, d, J=8.3 Hz), 
10.47 (lH, s) ppm. 
0-trity 1-cyanonilutamide-buty 1-triazoly lpentahy-
droxamic acid (38) 
Reaction of 26 with trifluoroacetic acid as described for 31 
gave the product 38 in 28% yield. HRMS (MALDI) calcu-
lated for [C24H28F3N7 0 4 +Ht536.2188. found 536.2230. 
0-trity 1-cyanonilutamide-buty 1-triazoly lheptahy-
droxamic acid (39) 
10 
0-trity 1-cyanonilutamide-buty 1-triazoly lheptahy-
droxamic acid ( 41) 
Reaction of 29 with trifluoroacetic acid as described for 31 
15 gave the product 41 in 49% yield. HRMS (MALDI) calcu-
lated for [C27H34F3 N7 0 4 +Ht578.2658. found 578.2678. 
20 
0-trity 1-cyanonilutamide-buty 1-triazoly loctahydrox-
amic acid (42) 
Reaction of30 with trifluoroacetic acid as described for 31 
25 gave the product 42 in 75% yield. 1H NMR (400 MHz, 
CDC13 ) ll 0.73-1.40 (!OH, m), 1.48 (6H, s), 1.52-1.62 (2H, 
m), 1.64-1.95 (6H, m), 2.05-2.20 (2H, m), 3.34 (2H, bs), 4.29 
(2H, bs), 7.89 (lH, s), 7.95 (lH, s), 8.09 (lH, s) ppm. 
Reaction of 27 with trifluoroacetic acid as described for 31 
gave the product 39 in 38% yield. HRMS (MALDI) calcu- 30 
lated for [C25H30F3N7 0 4 +Ht550.2345. found 550.2383. 
Additional Synthesis: 
Additional active compounds of the present invention are 
synthesized in accordance with Scheme 2 below: 
SCHEME2 
H2N~ 
'f OH NCX~~ ±0 CN 43 i)TEA, THF 0 N S 
s reflux ~ ~c ¢l ~N ii) 2N HCl, MeOH Cul, DIPEA, s DMSO,rt,Ar Cl)lCl ~ CN CF3 CF3 CF3 45 
CN CN 
44 
I ±N~ ~~ ~ 0 NAS H2N>Zyo fl 44 ¢l - -~ o, #' CF3 
2 CN 
46 47 
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Br 
XH 
i) 45° C. NaH, 
0 ~ ~ ~NH2 YBr DIPEA -CF3 ii) 0° C. NaH, CN 
0 
Br ~ ~OR 
R~Et,n~3 
R~H,n ~4-9 
Br 
NaN3 
70' C. 
---
TFA:DCM (0.2:10)1 
TIPS (drop wise) 
CN 
48 
KOH,-- 6, R ~Et, n ~ 3 
~ 7,R~H,n~3 
8, R~H,n~4 
9, R~H,n~5 
10,R~H,n~6 
11,R~H,n~7 
12,R~H,n~8 
50, n ~ 3 
51,n ~4 
52, n ~ 5 
53, n ~ 6 
54, n ~ 7 
55, n ~ 8 
CF3 Qs 
O)l_Cl 
Coupling 
Reagent 
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56, n ~ 3 
57, n ~4 
58, n ~ 5 
59, n ~ 6 
60, n ~ 7 
61, n ~ 8 
Trityl 
62, n ~ 3 
63, n ~ 4 
64, n ~ 5 
65, n ~ 6 
66, n ~ 7 
67, n ~ 8 
42 
d ' 
OJ::>..; 
~ CF3 
CN 
49 
0 
N3 ~ ,..o, ~N Trityl 
H 
13,n ~ 3 
14, n ~ 4 
15,n ~ 5 
16,n ~ 6 
17, n ~ 7 
18,n ~ 8 
/ 
Cul,DIPEA, 
DMSO,rt,Ar 
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N -LN/R-(]~)voH 
OANAO H 
A YCF3 
CN 
R'= 
68, n ~ 3 
69, n ~ 4 
70, n ~ 5 
71, n ~ 6 
72, n ~ 7 
73, n ~ 8 
74, n ~ 3 
75, n ~4 
76, n ~ 5 
77, n ~ 6 
78, n ~ 7 
79, n ~ 8 
80, n ~ 3 
81, n ~4 
82, n ~ 5 
83, n ~ 6 
84, n ~ 7 
85, n ~ 8 
PANEL 2 OF 2 
Biological Activity. 
Antiproliferative assays and In vitro binding assays were 
performed on the following compounds: 
R'~ 
N 
\j_N/R-(1JlvoH 
OANAO H 
A YCF3 
CN 
Ary!Nil. 
31,n ~3 
32, n ~4 
33, n ~ 5 
34, n ~ 6 
35, n ~ 7 
36, n ~ 8 
Alkyl!Nil. 
37, n ~ 3 
38, n ~4 
39, n ~ 5 
40, n ~ 6 
41,n ~7 
42, n ~ 8 
Antiproliferative assays were performed on low passage 
25 
35 
40 
45 
50 
cells for a 72 hour drug incubation period, and read using 
colorimetric assays with 0.4% DMSO control. Data is given 60 
in FIGS. 3A-3B (*Greater than 50 µM IC-50.). 
In vitro Androgen receptor (AR) binding is shown in FIG. 
4. The phenyl head group (Ary! Nil. HDACi) and the alkyl 
head group (Alkyl Nil. HDACi) with various linkers (n=3-8), 
and Cyano-Nilutamide, were tested by competition against 
[ 3H] Mibolerone in vitro in cytosolic rat AR. 
We claim: 
1. A compound of Formula I: 
(I) 
wherein: 
AR is an aryl group or covalent bond; 
B' is absent or consists of a C1 _6 group, optionally contain-
ing one or more heteroatoms, wherein the carbon atoms 
and/or heteroatoms are in a linear arrangement; 
A is a linking group connected to AR, wherein A is selected 
from the group consisting of: 
US 9, 139,565 B2 
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Bis C1 -C11 linear alkyl optionally containing one or more 
double or triple bonds and/or --CH3 and/or CH2 CH3 
branching; 
ZBG is selected from the group consisting of 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
46 
Ks/s'Ri, 
and 
R1 and R2 are independently selected from of hydrogen or 
C1 to C8 alkyl or together form a group comprising 3-8 
carbon atoms that is selected from cycloalkyl or substi-
tuted cycloalkyl; 
R3 is H or a salt counter ion; 
R4 is acyl or alkyl; 
R5 is alkyl; and 
R6 and R7 are independently Hor alkyl; 
Wis selected from the group consisting ofO and S; 
Xis selected from the group consisting of cyano and nitro; 
Y is selected from the group consisting oftrifluoromethyl 
andiodo; 
or a pharmaceutically acceptable salt thereof. 
2. The compound of claim 1, wherein B' is absent. 
3. The compound of claim 1, wherein B' is Cl to C6 linear 
alkyl. 
4. The compound of claim 1, wherein AR is a covalent 
bond. 
5. The compound of claim 1, wherein AR is selected from 
the group consisting of: 
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35 
40 
45 
50 
55 
F 
60 
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where 
. oints to A and B'' or to A and l
·ndicates optional connectmg p . oup when B' is absent. 
f the hydantom gr . 
the nitrogen atom o . wherein Bis Cl to CS lmear 6. The compound of claim 1, 
alkyl. . 1 wherein R1 and R2 are each 
7 The compound of claim ' ou consisting ofH and Cl ind~pendently selected from t~ ;~or~ a C3 to CS cycloalkyl. 
to CS alkyl· orR1 andR2 toget e .. 
' f 1 · 1 wherem. 
8 The compound o c mm ' t i· s C 1 to C6 linear 
· d when presen B' is present or absent, an 
alkyl; 1 t bond and when an aryl 1 P or cova en ' h p AR is an ary grou . lected from t e grou d when present is se group, an 
consisting of: 
49 
-continued 
F 
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10 
15 
20 
25 
30 
35 
40 
where 
45 
d B' ortoAand 50 . t to A an ' t· C
ting pom s h B' is absen ' . I conne w en indicates opt10na fthe hydant in group 
the nitrogen atom o up consisting of: 
A is selected from the gro 55 
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-t{:r/ >f o>< 
:0~><. /);Z '& rn 
15 
20 
/o+N_o ;yo) ! . 
j N--:rr 
25 
)(/(;~ 30 
35 
40 
45 
50 
x~Uylr>-t 55 
60 
·>-------i'---· ~ ~' 65 
52 
-continued 
B is Cl to CS linear alkyl; 
ZBG is selected from the group consisting of 
h independently selected from the group R and R2 are eac 
1 I consisting ofH and Cl to CS alky;
h :D rm a C3 to cs cycloalkyl; or R1 and R2 toget er o 
R3 is H or a salt counter ion; 
R4 is acyl or alkyl; 
R is alkyl; and 
Rs d R are independently Hor alkyl. 
6 an 7 nd of claim 1 selected from the group con-9. The compou 
sisting of: 
53 
f~r 
0 N 0 
A YCF3 
CN 
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31 32 
33 34 
±~i ~' 
ONO ~OH
0 
I 
CF3 
CN 
35 
36 
0 
37 38 
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39 40 
41 
--L~h~N,,oH OANAO H 
A YCF3 
c 
Ill 
N 
--LN~! 
OANAO 
A YCF3 
c 
Ill 
N 
and pharmaceutically acceptable salts thereof. 
10. The compound of claim 1, wherein ZBG is hydroxamic 
acid. 
11. The compound of claim 1, wherein ZBG is hydroxamic 
acid and Wis S. 
12. A pharmaceutical composition comprising an effective 
amount of the compound of claim 1 in combination with a 
pharmaceutically acceptable diluent, excipient, or carrier. 
13. A method of treating prostate cancer in a human or 
animal subject comprising administering said subject an 
effective amount of a compound of claim 1. 
42 
45 14. The method of claim 13, wherein ZBG is hydroxamic 
acid. 
15. The method of claim 13, wherein and ZBG is hydrox-
amic acid and Wis S. 
50 
16. The method of claim 13, wherein the prostate cancer is 
selected from hormone sensitive prostate cancer and hormone 
refractory prostate cancer. 
17. The method of claim 13, wherein the compound is 
administered enterally or parenterally. 
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